Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Eric and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's investor conference call. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Please note this event is being recorded. I'll now turn the call over to Tram Bui, HALO-ZIM's Vice President of Investor Relations and Corporate Communications. Please go ahead. Thank you, Operator. Good morning and welcome to HALO-ZIM's Investor Conference Call. In addition to the press release issued earlier this morning, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, HALO-ZIM's President and Chief Executive Officer, We will provide an update on our business and provide preliminary 2025 revenue estimates in addition to an update to our 2026 to 2028 financial guidance. On today's call, we will be making forward-looking statements as outlined on slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in the press release and slide presentation. I will now turn the call over to Dr. Helen Torley. Thank you, Tram, and thank you all for joining us this morning. The fourth quarter, and specifically the month of December, was a standout period for Halazem. Never before have we executed on such a broad...